|
Neurology - VNS Therapy |
||||
|
|
||||
|
Commercialisation Agency Strategic Marketing Consultancy News & Events |
||||
|
|
||||
| Aurora BioScience Neurolgy - VNS Therapy for Pharmacoresistant Epilepsy | ||||
|
Home
|
Aurora BioScience Neurology VNS Therapy for Pharmacoresistant Epilepsy
Safety and Prescribing Information
Indications for Use
The VNS Therapy System is indicated for use as an adjunctive therapy in reducing the frequency of seizures in patients whose epileptic disorder is dominated by partial seizures (with or without secondary generalisation) or generalised seizures that are refractory to antiepileptic medications.
Contraindications
The VNS Therapy System cannot be used in patients after a bilateral or left cervical vagotomy. Do not use short-wave diathermy, microwave diathermy or therapeutic ultrasound diathermy on patients implanted with the VNS Therapy System. Diagnostic ultrasound is not included in this contraindication.
Warnings
Neurologists
should inform patients about all potential risks and adverse events
discussed in the VNS Therapy System Physician’s Manual including
information that VNS Therapy may not be a cure for epilepsy. Since
seizures may occur unexpectedly, patients should consult with a
neurologist before engaging in unsupervised activities, such as
driving, swimming and bathing, or in strenuous sports that could
harm them or others.
Adverse Events
The most common
reported side effects from stimulation include hoarseness,
paresthesia (prickling feeling in the skin), dyspnea (shortness of
breath) and increased coughing. The most commonly reported side
effect from implant surgery is infection.
For more information on the VNS Therapy for pharmacoresistant epilepsy please contact us or visit the Cyberonics website. |
Products
|
||
|
Last Updated : 28 Mar 2007 |
||||
|
Privacy Policy Disclaimer Terms & Conditions Home ©2005-07 Aurora BioScience Pty Ltd |
||||